Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021
September 27, 2021 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
September 07, 2021 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting compounds designed to transform the standard of care for...
Cidara Therapeutics to Host Research and Development Day
September 02, 2021 08:00 ET
|
Cidara Therapeutics, Inc.
Virtual event will highlight the broad potential of the Cloudbreak® platform and the commercial potential for rezafungin Clinical thought leaders will highlight the risks of invasive fungal...
Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary
September 01, 2021 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...
Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
August 17, 2021 08:00 ET
|
Cidara Therapeutics, Inc.
Top-line data anticipated in late 2021 Single Phase 3 trial serves as basis for global regulatory filings SAN DIEGO and CAMBRIDGE, England, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cidara...
Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 12, 2021 16:43 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...
Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
August 05, 2021 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...
Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress
July 27, 2021 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...
Cidara Therapeutics Presents New Analyses from Multiple Rezafungin Studies at ECCMID 2021
July 12, 2021 08:00 ET
|
Cidara Therapeutics, Inc.
Oral presentation shows clinical data demonstrating clearance of infection in initial days of treatment of candidemia following one dose of rezafungin compared to multiple daily doses of standard of...
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 07, 2021 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...